文献速递艾滋病与性传播感染

法国2015/2016年未治疗慢性HIV感染者传播性耐药突变流行率稳定而非B亚型增加

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究在法国33个HIV临床中心纳入660例2015/2016年诊断的未治疗慢性HIV-1感染者,采用加权分析估计传播性耐药相关突变(TDRAMs)流行率,并与2010/2011年调查(n=661)比较。结果显示TDRAMs总流行率为10.8%(95%CI 8.4-13.2),与2010/2011年的9.0%(95%CI 6.8-11.2)相比无显著变化(P=0.269);非B亚型频率从42.9%升至54.8%(P<0.001),CRF02_AG从23.4%升至30.6%(P=0.004)。多因素分析显示感染B亚型的男性耐药病毒风险最高(调整OR=2.2,95%CI 1.3-3.9)。

要点

  • 2015/2016年法国未治疗慢性HIV感染者TDRAMs流行率10.8%,与2010/2011年9.0%相比稳定。
  • 非B亚型频率从42.9%增至54.8%,CRF02_AG从23.4%增至30.6%。
  • 感染B亚型的男性耐药病毒风险最高(调整OR=2.2),需强化安全性行为宣教。

核心结论

  • 2015/2016年法国未治疗慢性HIV-1感染者TDRAMs总体流行率为10.8%,与2010/2011年的9.0%相比保持稳定。
  • 非B亚型在2010年后显著增加,感染B亚型的男性是耐药病毒风险最高的人群。

研究设计与样本

  • 在法国33个HIV临床中心纳入660例2015/2016年诊断的未治疗慢性HIV-1感染者,检测TDRAMs。
  • 采用考虑各中心随访患者数量的加权分析得出代表性估计,并与2010/2011年调查(n=661)用相同方法比较。

主要发现

  • 2010/2011年与2015/2016年调查纳入时中位CD4细胞计数分别为394和350/mm3(P=0.056),血浆HIV-1 RNA均为4.6 log10 copies/mL(P=0.360)。
  • 蛋白酶或逆转录酶TDRAMs流行率2010/2011年为9.0%(95%CI 6.8-11.2),2015/2016年为10.8%(95%CI 8.4-13.2),P=0.269。
  • 整合酶抑制剂TDRAMs未见显著增加(6.7% versus 9.2%,P=0.146)。
  • 非B亚型频率从42.9%升至54.8%(P<0.001),其中CRF02_AG从23.4%升至30.6%(P=0.004)。
  • 多因素分析显示感染B亚型的男性与其他人群相比耐药病毒风险最高(调整OR=2.2,95%CI 1.3-3.9)。

临床怎么用

  • 在法国等类似流行背景地区,未治疗慢性HIV感染者启动抗逆转录病毒治疗前应进行基因型耐药检测,因TDRAMs流行率约10%。
  • 非B亚型增加提示需关注亚型多样性对耐药检测和传播风险的影响。
  • 针对感染B亚型的男性人群应重新强调安全性行为信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We estimated the prevalence of transmitted-drug-resistance-associated mutations (TDRAMs) in antiretroviral-naive chronically HIV-1-infected patients. PATIENTS AND METHODS: TDRAMs were sought in samples from 660 diagnosed HIV-1-infected individuals in 2015/2016 in 33 HIV clinical centres. Weighted analyses, considering the number of patients followed in each centre, were used to derive representative estimates of the percentage of individuals with TDRAMs. Results were compared with those of the 2010/2011 survey (n = 661) using the same methodology. RESULTS: At inclusion, median CD4 cell counts and plasma HIV-1 RNA were 394 and 350/mm3 (P = 0.056) and 4.6 and 4.6 log10 copies/mL (P = 0.360) in the 2010/2011 survey and the 2015/2016 survey, respectively. The frequency of non-B subtypes increased from 42.9% in 2010/2011 to 54.8% in 2015/2016 (P < 0.001), including 23.4% and 30.6% of CRF02_AG (P = 0.004). The prevalence of virus with protease or reverse-transcriptase TDRAMs was 9.0% (95% CI = 6.8-11.2) in 2010/2011 and 10.8% (95% CI = 8.4-13.2) in 2015/2016 (P = 0.269). No significant increase was observed in integrase inhibitor TDRAMs (6.7% versus 9.2%, P = 0.146). Multivariable analysis showed that men infected with the B subtype were the group with the highest risk of being infected with a resistant virus compared with others (adjusted OR = 2.2, 95% CI = 1.3-3.9). CONCLUSIONS: In France in 2015/2016, the overall prevalence of TDRAMs was 10.8% and stable compared with 9.0% in the 2010/2011 survey. Non-B subtypes dramatically increased after 2010. Men infected with B subtype were the group with the highest risk of being infected with a resistant virus, highlighting the need to re-emphasize safe sex messages.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Assoumou L, Bocket L, Pallier C, et al. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. J Antimicrob Chemother. 2019. PMID: 30753724. doi:10.1093/jac/dkz011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。